Compare · DFTX vs SMFL
DFTX vs SMFL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Smart for Life Inc. (SMFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. DFTX focuses on Medicinal Chemicals and Botanical Products, while SMFL focuses on Medicinal Chemicals and Botanical Products .
- DFTX carries a market cap of $4.39B.
- DFTX has hit the wire 10 times in the past 4 weeks while SMFL has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 0 for SMFL).
- Company
- Definium Therapeutics Inc.
- Smart for Life Inc.
- Price
- -
- -
- Market cap
- $4.39B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 10
- 0
- Recent ratings
- 8
- 0
Smart for Life Inc.
Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements; dietary supplements; nutritional supplements for athletes and active lifestyle consumers comprising powders, tablets, and soft gels; and various nutritional supplements. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Miami, Florida.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
- Definium Therapeutics Announces New Employee Inducement Grants
Latest SMFL
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 25-NSE filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SEC Form SC 13G/A filed by Smart for Life Inc.
- SEC Form NT 10-Q filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Smart for Life Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Smart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring Efforts
- Smart for Life Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing